Know Cancer

or
forgot password

Pilot Project for Anal Dysplasia Screening in Women With Cervical or Vulvar Dysplasia


N/A
18 Years
N/A
Not Enrolling
Female
Cervical Intraepithelial Neoplasia Grade 1, Cervical Intraepithelial Neoplasia Grade 2, Cervical Intraepithelial Neoplasia Grade 3, Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Stage 0 Cervical Cancer, Stage 0 Vaginal Cancer, Stage 0 Vulvar Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IV Vulvar Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer

Thank you

Trial Information

Pilot Project for Anal Dysplasia Screening in Women With Cervical or Vulvar Dysplasia


OBJECTIVES:

I. To evaluate the risk of anal dysplasia in women with cervical or vulvar dysplasia.

OUTLINE:

Patients undergo colposcopy and cervical Papanicolaou test with Human papillomavirus (HPV)
test followed by anal Papanicolaou test and high resolution anoscopy. Patients with
dysplastic anal lesions undergo repeat anoscopy at 3, 9, 15, and 24 months. Patients with
normal anoscopy are followed up at 1 and 2 years.


Inclusion Criteria:



- Histological confirmation of cervical, vaginal or vulvar intraepithelial neoplasia or
cancer are included

- Individuals treated with prior radiation therapy and/or chemotherapy are allowed

- Women with high-grade dysplasia (carcinoma in situ) are eligible, regardless of their
dysplasia free interval

- HIV-positive (Human Immunodeficiency Virus) and HIV-negative women will be enrolled;
HIV testing will not be performed as part of the study

Exclusion Criteria:

- Women who are not able to consent are excluded

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening

Outcome Measure:

Risk of anal dysplasia in women with cervical or vulvar dysplasia

Outcome Time Frame:

Over 2 years

Safety Issue:

No

Principal Investigator

Amy Halverson

Investigator Role:

Principal Investigator

Investigator Affiliation:

Northwestern University

Authority:

United States: Institutional Review Board

Study ID:

NU 10G02

NCT ID:

NCT01313104

Start Date:

Completion Date:

Related Keywords:

  • Cervical Intraepithelial Neoplasia Grade 1
  • Cervical Intraepithelial Neoplasia Grade 2
  • Cervical Intraepithelial Neoplasia Grade 3
  • Recurrent Cervical Cancer
  • Recurrent Vaginal Cancer
  • Recurrent Vulvar Cancer
  • Stage 0 Cervical Cancer
  • Stage 0 Vaginal Cancer
  • Stage 0 Vulvar Cancer
  • Stage I Vaginal Cancer
  • Stage I Vulvar Cancer
  • Stage IA Cervical Cancer
  • Stage IB Cervical Cancer
  • Stage II Vaginal Cancer
  • Stage II Vulvar Cancer
  • Stage IIA Cervical Cancer
  • Stage IIB Cervical Cancer
  • Stage III Cervical Cancer
  • Stage III Vaginal Cancer
  • Stage III Vulvar Cancer
  • Stage IV Vulvar Cancer
  • Stage IVA Cervical Cancer
  • Stage IVA Vaginal Cancer
  • Stage IVB Cervical Cancer
  • Stage IVB Vaginal Cancer
  • Neoplasms
  • Uterine Cervical Neoplasms
  • Vaginal Neoplasms
  • Vulvar Neoplasms
  • Cervical Intraepithelial Neoplasia
  • Uterine Cervical Dysplasia
  • Carcinoma in Situ

Name

Location